Levonis Adulti

Flunisolide, the active ingredient in Levonis Adulti, is a glucocorticoid presented as an inhalation formulation for inhalation use. It reduces airway inflammation and is indicated for the management of asthma and allergic rhinitis in adult patients.

GNH USA supplies Levonis Adulti as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Customers benefit from comprehensive technical support, documentation, and timely delivery across multiple continents.

Flunisolide is a glucocorticoid used to manage inflammatory airway conditions.

Asthma: reduces airway hyperresponsiveness and inflammation, improving breathing control. Allergic rhinitis: alleviates nasal congestion, sneezing and itching by decreasing mucosal inflammation. Seasonal allergic rhinitis: provides symptom relief during pollen seasons by suppressing allergic airway responses.

Flunisolide may cause a range of adverse reactions, most of which are related to its local anti‑inflammatory activity in the respiratory tract.

Common Side Effects: - Oral thrush (candidiasis) - Hoarseness or dysphonia - Cough or throat irritation - Headache - Nasal dryness - Mild epistaxis

Serious or Rare Side Effects: - Adrenal suppression - Osteoporosis with long‑term use - Cataracts or glaucoma - Severe allergic reaction (anaphylaxis) - Immunosuppression leading to opportunistic infections - Hyperglycemia in susceptible individuals

When prescribing or dispensing Levonis Adulti, consider the following safety measures.

Assess for active respiratory infection before initiating therapy. Monitor for signs of oral candidiasis and advise proper oral hygiene. Use a spacer device to reduce oropharyngeal deposition. Avoid abrupt discontinuation; taper dose when long‑term therapy is stopped. Pregnancy safety is unknown; weigh benefits against potential risks. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Flunisolide can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Systemic corticosteroids: additive immunosuppressive effects. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase systemic exposure. - Live vaccines: risk of reduced vaccine efficacy and infection.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin): may modestly raise levels. - Diuretics: potential for fluid retention and electrolyte imbalance. - Beta‑agonist bronchodilators: possible reduced bronchodilator response.